We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are going to take a look at where ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Shares of Merck & Co. Inc. MRK were unchanged Tuesday, on what proved to be an all-around dismal trading session for the ...

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

Shares of Merck & Co (MRK) continue to trend lower. If they reach the $95.00 level, there is a good chance they find support ...

Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my ...

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...